InvestorsHub Logo
icon url

Fox13

05/06/10 8:29 AM

#55614 RE: 3xBuBu #55609

May 6 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

So....that's what it was...